Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE40792 E1
Publication typeGrant
Application numberUS 09/602,191
PCT numberPCT/AU1993/000230
Publication dateJun 23, 2009
Filing dateMay 19, 1993
Priority dateMay 19, 1992
Fee statusPaid
Also published asCA2136233A1, CA2136233C, DE69333624D1, DE69333624T2, EP0656786A1, EP0656786A4, EP0656786B1, EP0656786B2, EP1477178A2, EP1477178A3, US5830887, US6497906, US6562380, US6642212, US6987098, US7045155, US20030078214, US20040048812, US20040106561, US20040170713, US20070179099, US20110305782, US20120003337, WO1993023069A1
Publication number09602191, 602191, PCT/1993/230, PCT/AU/1993/000230, PCT/AU/1993/00230, PCT/AU/93/000230, PCT/AU/93/00230, PCT/AU1993/000230, PCT/AU1993/00230, PCT/AU1993000230, PCT/AU199300230, PCT/AU93/000230, PCT/AU93/00230, PCT/AU93000230, PCT/AU9300230, US RE40792 E1, US RE40792E1, US-E1-RE40792, USRE40792 E1, USRE40792E1
InventorsGraham Edmund Kelly
Original AssigneeNovogen Research Pty Ltd
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US RE40792 E1
Abstract
Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia.
Images(16)
Previous page
Next page
Claims(19)
1. A method for treating or reducing the predisposition to a condition selected from the group consisting of benign breast disease, or cancer of the prostate, or elevated blood cholesterol, said method comprising administering to a subject having said condition or predisposed to said condition to a therapeutically effective amount of a health supplement composition comprising an extract from soya or clover, said composition comprising any two or more phyto-estrogens phyto-oestrogens of the group Genistein, Daidzein, Biochanin A, Formononetin or the natural glycosides of any of said phyto-estrogens phyto-oestrogens.
2. A method according to claim 1, wherein said composition is administered for treating benign breast disease.
3. The method according to claim 1, wherein said phyto-oestrogen is phyto-oestrogens are extracted from soy.
4. The method according to claim 3, wherein said phyto-oestrogen is phyto-oestrogens are extracted from soy hypocotyls.
5. A method according to claim 1, wherein said phyto-oestrogen consists phyto-oestrogens consist essentially of (a) genistein and (b) daidzein component, wherein component (a) optionally contains biochanin A, and component (b) optionally contains formononetin, and the ratio of a):b) (a) to (b) is about 1:2 to 2.1.
6. The method according to claim 1, wherein the phyto-oestrogen is said phyto-oestrogens are administered in an amount of from about 20 mg to 200 mg per day.
7. The method according to claim 1, wherein the phyto-oestrogen is said phyto-oestrogens are administered in an amount of from about 50 mg to 150 mg per day.
8. The method according to claim 1 whereby the phyto-oestrogen is said phyto-oestrogens are administered at least daily, over a period of at least a month.
9. A method according to claim 1, wherein said composition is administered for treating or reducing the predisposition to elevated levels of cholesterol in the blood stream.
10. A method according to claim 1, wherein said composition is administered for treating cancer of the prostate.
11. A pharmaceutical preparation, in solid dosage unit form, the having a biologically active component of said preparation comprising phyto-oestrogens consisting essentially of any two or more concentrated, phytoestrogen-derived isoflavones selected from the group consisting of Genistein, Daidzein, Biochanin A, Formononetin (a) genistein component and (b) daidzein component, wherein component (a) optionally contains biochanin A, and component (b) optionally contains formononetin, or the natural glycosides of any of said phytoestrogens and phyto-oestrogens, and wherein the ratio of (a) to (b) is about 1:2 to 2:1, said preparation including a pharmaceutically acceptable carrier.
12. A pharmaceutical preparation, as claimed in claim 11, wherein said solid dosage unit is selected from the group consisting of a pill, tablet, coated tablet, capsule or powder.
13. A pharmaceutical preparation, as claimed in claim 12, wherein said isoflavone is phyto-oestrogens are present in said solid dosage unit in an amount from about 20 mg. to about 200 mg. per dosage unit.
14. The pharmaceutical preparation according to claim 11, wherein said phyto-oestrogens are extracted from soy.
15. The pharmaceutical preparation according to claim 14, wherein said phyto-oestrogens are extracted from soy hypocotyls.
16. A method for treating or reducing the predisposition to a condition selected from the group consisting of benign breast disease, cancer of the prostate, or elevated blood cholesterol, said method comprising administering to a subject having said condition or predisposed to said condition a therapeutically effective amount of a health supplement composition comprising an extract from soy or clover, said composition comprising phyto-oestrogens, wherein the phyto-oestrogens consist essentially of (a) genistein and (b) daidzein, wherein component (a) optionally contains biochanin A, and component (b) optionally contains formononetin, wherein the ratio of (a) to (b) is about 1:2 to 2:1.
17. The method according to claim 16, wherein said phyto-oestrogens are administered in an amount of from about 20 mg to 200 mg per day.
18. The method according to claim 16, wherein said phyto-oestrogens are administered in an amount of from about 50 mg to 150 mg per day.
19. The method according to claim 16 wherein said phyto-oestrogens are administered at least daily, over a period of at least a month.
Description
TECHNICAL FIELD

This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen metabolites, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example.

BACKGROUND ART

The particular product in accordance with the invention is an extract of certain plants with the particular purpose of enrichment for phyto-oestrogens, both in their natural state and their closely related derivatives and metabolites.

Plants which are used as foodstuffs or medicinal herbs contain a wide variety of chemicals which are assimilated into the body following ingestion. Some of these chemicals are important nutrients for man and animals (e.g. fats, carbohydrates, proteins, vitamins, minerals) while others have none, or little or no known nutritional value. The phyto-oestrogens hitherto have fallen into this latter category of no known nutritional value.

There are 3 principal classes of phyto-oestrogens, viz. isoflavones, lignans, and coumestans. The isoflavones are thought to have a broad range of biological functions in plants, although these are poorly understood. However, two particular functions are recognised—(a) as phyto-alexin or stressor chemicals which are secreted by the plant in response to attack by parasites such as insects, fungi, viruses, etc. and which display activity against these parasites, and (b) chemicals which encourage colonisation of nitrogen-fixing bacteria on the roots of legumes. The biological functions in plants of the lignans and coumestans is not generally understood.

The different types of phyto-oestrogens are as follows.

Type 1 phyto-oestrogens—(isoflavones)

Isoflavones appear to be widely distributed in the plant kingdom and over 700 different isoflavones are described. However, the isoflavones which display oestrogenic activity belong to a small sub-group and are restricted almost exclusively to the Leguminosae family. The known oestrogenic isoflavones are daidzein, formononetin, genistein and biochanin A. In common human foodstuffs such as soya, chickpeas, lentils and beans, the total levels of the oestrogenic isoflavones range between about 40 and 300 mg per 100 g dry weight.

In the raw plant material, isoflavones occur principally as glycosides. Following ingestion by man and animals, the glycoside moiety is hydrolysed free by a combination of gastric and hydrolysis and fermentation by intestinal bacteria. Some of the isoflavones in the algucone form are absorbed directly and circulate in the blood, while the remainder are metabolised by intestinal fermentation to a variety of compounds which are also absorbed. The absorbed isoflavones and their metabolites appear to undergo little or no further metabolism in the body, being readily transported in the bloodstream, and ultimately being excreted in the urine.

Type 2 phyto-oestrogens (lignans).

Lignans are widely distributed in the plant kingdom. Over one hundred lignans are described and they are reported in common human foodstuffs such as cereals, fruits and vegetables. Oilseeds such as flax (linseed) have the highest known levels at 20-60 mg/100 g dry weight, while cereals and legumens have much lower levels at 0.3-0.6 mg/100 g, and vegetables even lower levels at 0.1-0.2 mg/100 g. The most common lignan described is metairesinol. Dietary lignans also appear to be metabolised fairly efficiently within the gut by bacterial fermentation, yielding metabolites such as enterodiol and enterolactone which are absorbed into the bloodstream and excreted in the urine.

Type 3 phyto-oestrogens (coumestans).

Compared to isoflavones and lignans, oestrogenic coumestans appear to have a relatively restricted distribution in plants and generally occur at much lower levels. Alfalfa, ladino clover and some other fodder crops such as barrel medic may have significant levels and have been reported to cause reproductive dysfunction in grazing animals. In the human diet, the important sources of coumestans are sprouts of soya and alfalfa where levels up to 7 mg/100g dry weight are reported. Whole soyabeans and other common foodstuff legumes contain levels of approx. 0.12 mg/100 g dry weight and most of that is concentrated in the seed hull which commonly is removed in the preparation of human foodstuffs.

Type 4 phyto-oestrogens (oestrogens).

These are compounds closely related to animal oestrogens such as oestrone, oestradiol and oestriol. These have been described in plants such as liquorice, apple, French bean, pomegranate and date palm. Little is known of the metabolism and biological significance of these chemicals in humans and animals.

The full range of biological effects in animals of these dietary phyto-oestrogens has received only recent study. A primary effect appears to be associated with their close structural relationship to naturally-occurring oestrogens which allows the phyto-oestrogens to mimic the effects of the endogenous oestrogens. The known biological effects of phyto-oestrogens can be summarised thus:

In vitro:

    • (a) bind to both cytoplasmic and nuclear membrane (Type II) oestrogen receptors on human tissues;
    • (b) strongly compete with oestrogens for oestrogen receptors, but only weakly stimulate those receptors;
    • (c) strongly stimulate the production of sex hormone-binding globulin (SHBG) from human cells;
      In vivo
    • (d) weakly oestrogenic in animals;
    • (e) competitively-inhibit the response of tissue to oestrogens.

The three major types of phyto-oestrogens appear to act at the cellular level in a similar manner, that is through interaction with cell surface oestrogen receptors. In the body, naturally-occurring oestrogens circulating in the blood largely exert their activity by interaction with oestrogen receptors on cell surfaces; such interactions then triggering a particular biological function of that particular cell. Phyto-oestrogens are able to bind to those oestrogen receptors because the structure of these compounds so closely resembles the endogenous oestrogens, but unlike the animal oestrogens, phyto-oestrogens only weakly activate the oestrogen receptor.

As a result of phyto-oestrogens and endogenous oestrogens competing for the oestrogen-binding sites on the cells, the more weakly oestrogenic phyto-oestrogens can be considered to have an anti-oestrogenic effect. This phenomenon is known as competitive-inhibition, by which is meant that the biological effect of an active substance is impaired by the competitive binding to a target receptor of a similar but less active compound.

Thus a primary biological effect of phyto-oestrogens is held to be competitive inhibition of endogenous oestrogens. However, another more direct effect is the stimulation of synthesis of SHBG in the liver, as occurs with orally administered synthetic steroidal oestrogens. High levels of dietary phyto-oestrogens are thought to be responsible for the higher SHBG levels seen in vegetarians and in cultures maintaining traditional (high legume-containing) diets.

At high levels, dietary phyto-oestrogens can have profound physiological effects. An example of this is sheep and cattle gazing pastures containing a high proportion of subterranean clover or red clover which can contain levels of phyto-oestrogens as high as 5% of the dry weight of the plant. As a result of the competitively-inhibitory effect of the dietary phyto-oestrogens on endogenous oestrogen function in the hypothalamus, male and female sheep and cows can develop androgenic symptoms.

Such high dietary levels of phyto-oestrogens, however, are rare. It is far more common that most animal and human diets contain low to moderate levels of phyto-oestrogens, and there is growing epidemiological evidence that such levels have a beneficial effect on human health.

In most traditional human diets in developing countries, the principal phyto-oestrogens consumed are isoflavones because of the generally high reliance on legumes (also known as pulses) as a source of protein. The general consumption rates (g/day/person) for legumes for different regions currently are approximately: Japan (50-90), India (40-80), South America (30-70), North Africa (40-50), Central/Southern Africa (20-50) and Southern Mediterranean (30-60). Legumes also are a source of lignans and, to a much lesser extent, coumestans, and the additional cereal and vegetables in the diet would also boost the lignan intake. However, the isoflavone intake in these traditional cultures with high legume consumption would typically be much in excess of either lignan or coumestan intake.

The major types of legumes used in traditional diets include soya, chickpeas, lentils, ground nuts, beans (e.g. broad, haricot, kidney, lima, navy), and grams (bengal, horse and green).

In Western, developed countries, the daily intake of dietary phyto-oestrogens generally is negligible to low. In Western Europe, North America and Australasia, legumes were a major source of protein for the majority of the populations up to the end of the 19th century. From that time, legume consumption has declined significantly, being replaced in the diet with protein of animal origin. Average legume consumption in these regions currently is between 5-15 g/day/person with a significant proportion of the population ingesting little or no legumes or other phyto-oestrogen containing foods on a regular basis. Moreover, the types of legumes consumed in these regions (e.g. garden peas, French beans) have a typically lower isoflavone content than legumes such as soya and chick peas.

Based on the typical consumption rates and types of foodstuffs consumed, the typical phyto-oestrogen intake (mg/day) for different regions can be calculated approximately as

Isoflavones Lignans Coumestans
Japan 50-300 2-5 0.5
Australia 2/25 1-5 0.2

Thus it can be seen that regions which have maintained traditional diets have a higher average daily intake of phyto-oestrogens, particularly isoflavones, compared to western countries. People in communities such as Japan or developing countries with high legume intake excrete substantially higher phyto-oestrogen metabolites in their urine compared to people in Western countries. Within the latter, vegetarians also excrete higher phyto-oestrogen metabolite levels than do those consuming a more typical, omnivorous Western diet.

The presence of relatively large amounts of phyto-oestrogen metabolites in urine serves to highlight their potential biological significance. It has been shown that total urinary excretion of isoflavones and their active metabolites in people consuming moderate amounts of legumes is greatly in excess (up to 10,000×) of steroidal oestrogen levels. So that while the oestrogenicity of isoflavones to oestrogen receptors is only about 1% that of endogenous oestrogens, this weaker effect is off-set by the much higher blood levels of the isoflavones.

It is known that legumes have formed an important part of the human diet over the past 20,000-30,000 years. It therefore follows that human metabolism has evolved over at least this period in the presence of relatively large levels of dietary phyto-oestrogens, particularly isoflavones. Given the known biological effects of phyto-oestrogens, it also follows that endogenous oestrogen metabolism and function has evolved in the face of significant competitive inhibiting effects of phyto-oestrogens. It has been speculated that the presence of significant dietary levels of phyto-oestrogens in recent human evolution has led to a degree of adaption by tissues responsive to reproductive hormones to these dietary components. That is, both the rate of production and/or the function of endogenous oestrogens may be either dependent upon or influenced by the presence of phyto-oestrogens in the body. It follows therefore that a relative deficiency of dietary phyto-oestrogens could be expected to lead to an imbalance of endogenous oestrogen metabolism.

There is increasing interest in the likely contribution of a relative deficiency of dietary phyto-oestrogens to the development of the so-called “Western diseases”, especially cancer of the breast, benign (cystic) breast disease, cancer of the uterus, cancer of the prostate, cancer of the bowel, premenstrual syndrome, menopausal syndrome, and atherosclerosis. All of these diseases are associated to a greater or lesser extent to oestrogen metabolism, and oestrogen function is either known or is suspected to play a role in their aetiology and/or pathogenesis.

Each of these diseases occurs at much higher incidence in Western, developed countries than it does in developing communities. Moreover, it is thought that in Western communities, the incidences of each have risen over the past century. It is also generally held, that of all the environmental factors likely to be contributing to this phenomenon, diet is the principal factor. Of those dietary components with the potential to influence the aetiology of oestrogen-related disease, there is a growing awareness that phyto-oestrogens may have important potential.

The beneficial effects of phyto-oestrogens on human health are thought to derive from at least two principal function, those being (i) competitive-inhibition of the function of endogenous oestrogens, and (ii) the stimulation of production of SHBG. SHBG plays an important role in primates in binding and transporting the reproductive hormones (oestrogens, androgens) in blood so that the availability of reproductive hormones is regulated to a large degree by SHBG levels. Higher SHBG levels are considered beneficial in leading to a reduction in both blood levels of unbound (and unregulated) reproductive hormones and metabolic clearance rates of the hormones. Although isoflavones are potent stimulators of SHBG synthesis, they only weakly bind to SHBG, so that the increased SHBG levels resulting from the dietary isoflavones are largely available for binding to endogenous oestrogens.

In terms of directly identifying the beneficial effects of phyto-oestrogens in amelioration of any or all of the “Western diseases” there are only two examples. In one example, the diets of women, with menopausal syndrome were supplemented with foodstuffs (soya, linseed, red clover) high in phyto-oestrogens, and an alleviation of menopausal symptoms to an extent similar to that obtained with replacement therapy with synthetic oestrogens was achieved; that effect was ascribed to the phyto-oestrogen content of the supplement. In the other example, legumes such as soya and various pulses have been shown to have a hypocholesterolaemic effect in humans; this effect has not been ascribed to phyto-oestrogens, although purified isoflavones do have a hypocholesterolaemic effect in animals with artifically-induced hypercholesterolaemia.

In summary, it could reasonably be deduced that the inclusion of greater levels of foodstuffs high in phyto-oestrogens in the standard diets of men and women in developed countries could be expected to redress a general imbalance of endogenous reproductive hormone metabolism, thereby reducing the predisposition of those communities to the above diseases. While there are various types of phyto-oestrogens which may be suitable to this end, the large discrepancy in isoflavone consumption between communities with Western and traditional diets suggest that foodstuffs with high isoflavone content are of prime interest.

However it is unrealistic to expect that public education programmes would readily convert communities in developed countries from a diet where the protein content is predominantly animal-derived, to one where the protein is predominantly legume-derived. Moreover, the legumes which are commonly consumed in developed countries are relatively poor sources of phyto-oestrogens and the general acceptance in the community of less well-known legumes with higher phyto-oestrogen content would be necessarily a slow process. Also, the highly variable levels of phyto-oestrogens in foodstuffs relating to plant strain type, degree of plant maturity, and climatic and other environmental conditions suggests that the supply of an assured amount of phyto-oestrogens through the use of whole foodstuffs may be difficult.

An alternative strategy it to make available either (i) phyto-oestrogens in a purified form, or (ii) foodstuffs which are enriched for phyto-oestrogens. In this way, the phyto-oestrogen could be added to the diet in a convenient form as a supplement without requiring any substantive change to the diet.

DISCLOSURE OF INVENTION

The present invention concerns a health supplement specifically enriched for isoflavones selected from genistein, daidzein, formononetin and biochanin A, or their natural glycoside form, or their analogues, in sufficient amounts to improve the health of a human.

Preferably the supplement contains an excipient, a diluent, a carrier or the like, or else the supplement is mixed with food or can be consumed directly. It is also preferred that foodstuffs, are readily available, have no known toxic components, and are rich sources of isoflavones; such foodstuffs preferably being red clover or soya. It is also preferred that the ratio of genistein and/or it methylated derivative biochanin A to daidzein and/or its methylated derivative formononetin is between 1:2 to 2:1. Other plant components with oestrogenic activity including lignans, coumestans and flavones may also be present in the extract, but is held that these are of secondary importance to the predominant isoflavones. The term phyto-oestrogens is used hereafter to indicate a predominance of isoflavones with lesser amounts of lignans, coumestans and flavones.

The invention also concerns a method of improving the health of a human by administering to the human a sufficient amount of phyto-oestrogen. Ideally, the phyto-oestrogen is administered regularly on a daily basis over a sufficient period such as at least a month. The health conditions which may be prevented or ameliorated include cancer of the breast, cancer of the prostate, cancer of the uterus, cancer of the bowel, benign (or cystic) breast disease, pre-menstrual syndrome (also known as pre-menstrual tension), or adverse symptoms associated with menopause in women. The method and supplement in accordance with the invention also improves the health of a human having elevated levels of blood cholesterol. The product also is useful in avoiding or ameliorating cancer in persons. The symptoms produced by these conditions and the general well-being is also improved by the use of these supplements.

The phyto-oestrogen in accordance with the invention may be obtained from a number of different sources. Preferably the phyto-oestrogens are extracted from a clover such as red clover or subterranean clover or from soya which contain high levels of phyto-oestrogens. However, any source rich in phyto-oestrogens may be used instead, if desired.

Various different isoflavones have been identified from these sources—they are principally genistein, biochanin A, daidzein, formononetin and glyciten. In plants these compounds occur principally in a glycoside form bound to sugars such as glucose, with smaller amounts present as the aglucone forms. The formulae of the isoflavones are:

The structure of biochanin A is the same as for genistein but with a 4′-methoxy group, and similarly formononetin has the same structure as daidzein, but with a 4′-methoxy group.

Following ingestion by humans, the glycosidic isoflavones are hydrolysed to the aglucone form and biochanin A and formononetin are demethylated by bacterial fermentation to genistein and daidzein respectively. A small proportion of these free isoflavones are absorbed directly from the bowel and circulate in the blood. The bulk of the isoflavones, however, remain in the bowel and undergo fermentation to form various metabolites which also are absorbed into the bloodstream. The principal metabolites which have been identified are equal to O-desmethylangolensin.

In vitro and in vivo studies have indicated that genistein, biochanin A, equol, daidzein, formononetin all have oestrogenic activity in descending order. O-desmethylangolensin is only very weakly oestrogenic and glycitein is non-oestrogenic

In animal and in vitro studies, genistein has been shown to have greater oestrogenic/anti-oestrogenic activity and SHBG-stimulating capacity than the other isoflavones or their metabolites (approximately 10 times that of daidzein and formononetin). However, the full range of biological effects of the different isoflavones have yet to be fully determined, and in particular their relative efficacies in the different biological effects such as oestrogenicity, hypocholesterolaemia, anti-anglogenesis, anti-oxidation, anti-carcinogenesis for example are not yet fully known.

It is thought that because the methyl forms (biochanin A and formononetin) ultimately are largely demethylated to their principals, genistein and daidzein, with improved biological efficacy, then it is unimportant whether the isoflavones are present in the claimed product in the methylated or demethylated forms.

Given that the relative biological importance of the two isoflavone groups (being genistein and daidzein) to human health remains unclear, and that each might indeed have different importance, plus the fact that both isoflavones are present in the diet in approximately equal proportions, then it is prudent that both isoflavones be present in the claimed product in approximately equal proportions.

Any leguminous plants such as detailed here could be used as sources of phyto-oestrogens (principally isoflavones with lesser amounts of lignans and coumestans): Indian liquorice (Abrus precatorius); various species of Acacia spp. including, A. aneura, A. cibaria, A. longifolia, and A. owaldii; ground nut (Apio tuberosa); ground pea (Arachis hypogea); milk vetch (Astragalus edulis); marama bean (Bauhinia esculenta); sword bean (Cajanus cajan indicus); jack bean (Canavalia ensiformis); sword bean (Canavalia gladiata); seaside sword bean (Canavalia rosea); various Cassia spp. including C. floribunda, C. laevigata, and C. occidentalis; carobbean (Ceratonia siliqua); chick pea (Cicer arietinum); yebnut (cordeauxia edulis); various Crotalaria spp. including C. laburnifolia, and C. pallida; cluster bean (Cyamopsis psoralioides); tallow tree (Detariaum senegalense); sword bean (Entada scandens); balu (Erythrina edulis); soyabean (Clycine max;) inga (Ingaedulis); Polynesian chestnut (Inocarpus fagifer); hyacinth bean (Lablab purpureus); grass pea or Indian vetch (Lathyrus sativus); cyprus vetch (Lathyrus ochrus); lentil (Lens culinaris); jumping bean (Leucaenal eucocephala); various Lupinus spp. including L. albus, L. luteus, L. angustifolium, L. mutabilis, and L. cosentiniij; ground bean (Macotylma geocarpa); horse gram (Macrotyloma uniflorum): alfalfa (Medicago sativa); velvet bean (Mucuna prureins); yam beans (Pachyrhyzuz erosus, P. tuberosus); African locust bean (Parkia clappertoniana); Parkia speciosa; oil bean tree (Pentaclethra macrophylla); various Phaseolus spp. including P. acutifolius, P. vulgaris, P. luntus, P. coccineus, P. adenathus, P. angulris, P. aureus, P. calcaratus, P. mungo, and P. polystachyus; garden pea (Pisum sativum); djenko bean (Pithecolobium lobatum); mesquite (various Prosopis spp.); geo bean (Psophocarpus scandens, P. tetragonolobus); various Psoralea spp.; Sesbania bispinosa; yam bean (Sphenostylis stenocarpa); tamarind (Tamarindus indica); fenugreek (Trigonella foenumgraecum); vetches (various Vivia spp. including V. sativa, V. atropurpurea, V. ervilia, and V. monantha); broad bean (Vicia faba); black gram (Vigna mungo); various Vigna spp. including V. radiata, V. aconitifolia, V. adanatha, V. angularus, V. tribolata, V. umbelata, and V. unguiculata; and earth pea (Voandzeia subterranea).

The ideal sources of phyto-oestrogens for preparation of a supplement in accordance with the invention are preferably those which (i) are readily available, (ii) are relatively inexpensive, (iii) are readily and economically processed so as to yield the extract, (iv) have a high isoflavone content so as to provide high yields, and (v) have no known toxic components requiring selective removal or inactivation.

Certain clovers, such as red clover (T. pratense) and subterranean clover (T. subterranean) are the preferred sources. On a dry weight basis, these clovers contain the highest amounts of oestrogenic isoflavones of all legumes tested to date with levels of 3-5 g % (T. subterranean) and 1-3 g % (T. pratense). In comparison, soya flour has a level of 0.15-0.30 g %, lentils (0.08-0.12 g %), chick peas (0.07-0.13 g %), and garden peas (0.02-0.03 g %). Thus it can be seen that clovers contain approximately at least 10-30 times by weight the isoflavone content of other commonly available, human leguminous foodstuffs meaning that for manufacturing purposes, the yield of isoflavones per unit weight of plant material is many times greater from clover than from other legumes.

Red clover and subterranean clover also are common fodder crops and are readily grown and are widely available. Clovers also are comparatively cheaper ($200/tonne) than crops such as soya and lentils ($500/tonne).

With clovers, the isoflavones are recovered from the leaf rather than from the seed in the case of soya, beans, nuts and grams. This provides a substantially higher yield of isoflavones per unit area of pasture for clovers compared to other legumes because of the greater leaf matter compared to seed matter recovered per plant.

Clovers also have an extended growing season, and faster growth rates compared to those legumes such as soya, lentils or chick peas where the seed is the end-product. Clover can be cropped for its leaf content repeatedly over a single growing season. An additional benefit of this is that as phyto-alexins, the isoflavones content increases in response to the stress of cropping.

Thus it can be seen that in clovers versus other legumes provide a combination of (a) higher isoflavone content per dry weight of plant, (b) a higher yield of dry matter containing isoflavones per plant, and (c) a higher yield of dry matter per hectare.

An additional feature of clovers is that there are wide varieties of cultivars with widely differing isoflavone levels and types. This allows blending of different cultivars to achieve the desired ratio of the different isoflavones, although it is equally possible to use a single cultivar which provides the desired ratio.

Other legumes such as soyabean flour may be used for enrichment of phyto-oestrogens but the substantially poorer (approx. 10%) yield of isoflavones compared to clovers means that the manufacturing costs are substantially greater and there is substantially greater amounts of waste products which requires disposal or further treatment for re-use as a foodstuff. An alternative, however, to the use of whole soya for this purpose, is to use the hull, and hypocotyl (or germ) of the hole soyabean. The hull and hypocotyl represent only a small proportion by weight (8% and 2% respectively) of the intact bean. However, the coumestrol content of soya is concentrated in the hull, and the daidzein content of soya is concentrated in the hypocotyl. The two cotyledons which comprise the bulk of the soyabean (90% by weight) contain the bulk of the genistein content of soya. During standard processing of soyabeans, the hulls being a fibrous component with little or no perceived nutritional value normally are separated and removed by physical means. The hypocotyls become separated following the splitting of the cotyledons, and while these currently generally are not deliberately isolated, they may be separated and isolated by passing the disturbed soyabeans over a sieve of sufficient pore size to selectively remove the small hypocotyl. The hypocotyl contains approx. 1.0-1.5 g % isoflavones (95% daidzein, 5% genistein). The raw hypocotyl and hull material can be ground or milled to produce, for example, a dry powder or flour which then could be either blended or used separately by a dietary supplement in a variety of ways including, for example, as a powder, in a liquid form, in a granulated form, in a tablet or encapsulated form, or added to other prepared foodstuffs. Alternatively, it could be further processed to yield an enriched extract of phyto-oestrogens. Either or both of these materials also could be added to other leguminous material such as clover to provide the invention.

In plants, the oestrogenic isoflavones are restricted principally to the leaf, fruit and root; the stem and petiole contain very little. With soya and other common human legume foodstuff crops, the leaves are rarely regarded as foodstuff, indeed with these crops, the plants normally are allowed to die and dry out before the seed crop is harvested. Nevertheless, the fresh leaves of these crops could be regarded as a source of phyto-oestrogens for the invention although the much lower isoflavone content of the leaves of these crops compared to clovers, plus their generally slow growth compared to clovers, suggests that they would not be a preferred source of large-scale isoflavone enrichment.

To provide a similar amount of isoflavone to that contained in most traditional legume-rich diets (50-100 mg oestrogenic isoflavones/day) would require an average daily consumption of 3-6 g dry weight or 15-30 g wet weight of specially selected cultivars of clover with particularly high isoflavone levels. Clover grasses generally are not eaten by humans, except to a limited extent as sprouts of some of the pleasanter testing varieties. Isoflavones are intensely astringent and are responsible in large part for the bitter taste of legumes. Thus the types of bean sprouts, clover sprouts and alfalfa sprouts generally available have been selected on the basis of cultivar and of age for pleasant taste, and in so doing inadvertently have been selected for low isoflavone content. Of the sprouts currently available in Western countries for human consumption, between approx. 100-250 g would need to be consumed daily to provide a dosage of 50-100 mg isoflavones. Certainly clovers and other legume sprouts are not generally eaten in such sufficient quanitites by humans to obtain the advantages of the present invention.

The invention also concerns formulations containing the phyto-oestrogens discussed above together with a dietary suitable excipient, diluent, carrier, or with a food. Ideally the formulation is in the form of a pill, tablet, capsule, or similar dosage form.

The formulations may be a variety of kinds, such as nutritional supplements, pharmaceutical preparations, vitamin supplements, food additives or foods supplemented with the specified active phyto-oestrogens of the invention, liquid or solid preparations, including drinks, sterile injectable solutions, tablets, coated tablets, capsules, powders, drops, suspensions, or syrups, ointments, lotions, creams, pastes, gels, or the like. The formulations may be in convenient dosage forms, and may also include other active ingredients, and/or may contain conventional excipients, carriers and diluents. The inclusion of the subject phyto-oestrogens in herbal remedies and treatments is also a preferred part of the invention.

The invention is also directed to the amelioration, prevention, or of various conditions responsive to treatment with the phyto-oestrogen substances of the invention. The preferred amounts to be administered to the human fall within 20-200 mg on a daily basis. More preferably the dosage is from 50-150 mg on a daily basis, and most preferably at a dosage of about 100 mg. If desired greater dosages can be administered for therapeutic reasons. In contrast to prior practices such high dosages were not possible. For example, dosages of up to or greater than 1000 mg may be suitable to treat some conditions. In order to obtain the benefits of the invention, the treatment with the isoflavones should continue for a considerable period, ideally for at least a month, and ideally continuously for the whole period for which the heatlh improvement advantages should accrue.

The product according to the present invention yields a constant and accurately known amount of isoflavones. The product is also ideally a natural product, which has advantages for consumer acceptance, and in accordance with the supposed theory behind the invention may very possibly be one of the main causes for its beneficial effects. Whole legumes have a widely variable isoflavone content due to two main causes: the type of legume and the environmental effect. The type of legume typically has a wide range of isoflavone content. The miligram of isoflavone per hundred gram of whole foodstuff (dry weight) is given in the following table.

Soya Products
Whole Soya 150-300
Soya Milk 25-40 (mg per 200 ml)
Tofu 55-95
Lentils 80-120
Chickpeas 70-130
Broad beans 15-20
Garden peas 15-25

Thus common leguminous foodstuffs consumed in Western countries (broad beans, garden peas etc.) have relatively low oestrogenic isoflavone content and exceptionally large amounts of these would need to be consumed daily to approximate those isoflavone levels consumed in traditional diets. Most Western cultures do not traditionally eat legumes with high isoflavone contents, and those soya products (milk, tofu etc.) which are becoming increasingly popular in Western countries, also have relatively low isoflavone levels compared to whole soya, indicating that relatively large amounts of these would need to be consumed on a regular basis to deliver to the required isoflavone levels.

The environmental effect arises because the isoflavone levels in any species of plant depend generally on the age of the plant, the climatic conditions where it is grown, the fertiliser and so forth. Therefore constant and consistent dosage is very difficult with ordinary whole foodstuffs. The accurately determined quality and quantity of the active isoflavones in the product, and its easy consumability when compared with the almost impossible task of eating huge amounts of often practically inedible foods, is therefore an important feature of the invention for preventing and helping in overcoming various health problems.

Among the various health problems, the treatment or prevention of high blood cholesterol levels, and the treatment of PMS and menopausal symptoms is especially important. The product of the invention modulates the production and/or function of endogenous sex hormones in humans to modify or produce health improving effects, including the following: (i) lowered levels of various blood liproproteins including, for instance, low-density and very-low-density cholesterol leading to reduced risk of development of atherosclerosis, (ii) reduced risk of development of cancer of the prostate; (iii) reduced risk of cancer of the breast; (iv) reduced risk of development of cancer of the uterus; (v) reduced risk of development of cancer of the large bowel; (vi) reduced risk of development of the syndrome in women commonly referred to pre-menstrual syndrome (PMS), which includes pre-menstrual tension (PMT); (vii) reduced risk of development of many untowed symptoms (including dry vagina, peripheral flushing, depression etc.) commonly associated in women with menopause; and for treating benign breast disease in women (benign or cystic breast disease associated with non-malignant swelling and tenderness of breast tissue). The invention therefore is directed to a method for the prophylaxis or treatment of a human, to combat conditions associated with phyto-oestrogen deficiency, which comprises administering to the human an effective amount of phyto-oestrogen principally isoflavone but which might also include relatively smaller amounts of lignans and coumestans, ideally in a concentrated form, wherein the isoflavones include genistein, and/or biochanin A, and/or daidzein, and/or formononetin.

Cancer of the breast generally is considered to be associated with oestrogenic dysfunction. Breast cancer cells may display more oestrogen receptors than normal breast cells and stimulation of these receptors by endogenous oestrogens is thought to be a prime source of stimulation of their malignant growth. Currently synthetic anti-oestrogens are being used to prevent or treat the growth of malignant breast cells. Isoflavones are potent anti-oestrogens that could be expected to help prevent or to successfully treat breast cancer. It has been reported that the risk of breast cancer in western societies is indirectly proportional to the level of phyto-oestrogens in the diet and to the amounts of phyto-oestrogen metabolities excreted in the urine.

Cancer of the prostate generally is considered to be associated with sex hormone dysfunction and the growth of prostatic cancer cells is influenced by oestrogens and androgens. The incidence of prostatic cancer is low in communities with high legume intake and, conversely, is high in Western societies. Phyto-oestrogens are though to protect from development of prostatic cancer. One mechanism may be the effect of phyto-oestrogens on lowering the proportion of unbound:bound reproductive hormones in the blood. However, there is other evidence to suggest that phyti-oestrogens, particularly isoflavones, can have a direct influence on certain cellular enzymes within prostatic cells.

Pre-menstrual syndrome has uncertain aetiology and pathogenesis, although most certainly is associated with reproductive hormone dysfunction. It also is a syndrome which has reportedly lower incidence in communities maintaining traditional high-legume diets. It is proposed that phyto-ostroegens will alleviate this condition by restoring balance to oestrogen metabolism.

Menopausal syndrome is associated with changes in the oestrogen profile in the body with advancing age. Adverse clinical symptoms may be treated with oestrogen replacement therapy. There is evidence that foodstuffs high in phyto-oestrogens are a suitable alternative to synthetic hormones in this respect, producing alleviation of adverse clinical symptoms. Again, it is proposed that phyto-oestrogens will function by restoring balance to oestrogen metabolism.

Benign (or cystic) breast disease has unknown aetiology. However, its association in women with certain stages of the menstrual cycle is strongly suggestive of oestrogen dysfunction. There currently is no successful treatment of this condition. Phyto-oestrogens are proposed to successfully treat this condition by restoring balance to oestrogen metabolism. Atherosclerosis is associated with cholesterol metabolism which in turn is associated closely with oestrogen metabolism. The generally higher incidence of atherosclerosis in young men versus young women, the rising incidence in women following menopause, and the lower incidence in post-menopausal women receiving oestrogen replacement therapy, all point to the moderating influence of oestrogens on cholesterol metabolism. A prime effect of oestrogens on cholesterol metabolism is stimulation of the liver to process cholesterol, particularly the highly atherogenic low-density lipoproteins and very low-density lipoproteins, into bile salts. It is proposed that phyto-oestrogens have an important hypocholesterolaemic effect in humans. There may be a variety of mechanisms involved, but one may be the stimulation by phyto-oestrogens of cholesterol catabolism by the liver.

MODES FOR CARRYING OUT THE INVENTION

The invention is now described with reference to various examples.

EXAMPLE 1 Preparation of Red Clover Product

Tablets were prepared using red clover in accordance with the following procedure. The raw plant material is harvested and dried; such drying being either sun-drying or from applied heat. The dried product is then preferably chaffed, before the following extraction step, although this can be omitted if desired.

The dried material is extracted in an aqueous:organic solvent mix. The aqueous phase is required to extract the water-soluble glycoside form of isoflavones, while the organic solvent is required to solubilise the water-insoluble algycone form. The organic solvent can be either alcohol, chloroform, acetone or ethyl acetate. The ratio of solvent in the water can be between 0.1% and 99.9%. The preferred method is to use 60% alcohol in water.

The isoflavones are extracted by exposing the plant material to the water:solvent mix. The exposure time in general terms is indirectly proportional to the temperature of the mixture. The temperature of the mix can range between ambient temperature and boiling temperature. The exposure time can be between 1 hour and 4 weeks or even longer. It has been determined that the adequate items for maximal recovery of isoflavones are 2 weeks at 50° C. and 24 hours at 90° C. The supernatant is separated from the undissolved plant material and the organic solvent removed by distillation. The aqueous supernatant then is concentrated, typically by distillation.

Additional processing steps can be used, if desired, to convert the extracted natural product to capsule, tablet, or other convenient form for ingestion, using normal techniques for doing this. Otherwise the product can be packaged as a convenient food additive.

EXAMPLE 2 Preparation of Soya Hypocotyl Product

Soyabeans were heated in dry air so that the hull became brittle. The beans then were processed through a tumble mill which removed the hull and split the bean the two cotyledons and the small-sized hypocotyl which separated from each other. The light-weight hulls then were removed by an air stream. The small-sized hypocotyls were separated from with larger cotyledons by sieving through a steel wire mesh with apertures of 1 mm×1 mm. This yields approximately 87% purity of hypocotyls with 13% contamination of small cotyledon chips.

Normal soybean processing steps isolate the hulls and then these are discarded or processed separately for use in human and animal foodstuffs. The hypocotyls normally are not separated and are processed along with the cotyledons. However, a small number of soybean processors are separating hypocotyls by the above methods in order to reduce the astringent taste of soyflour for human consumption, and currently these hypocotyls are either discarded or processed to flour for use in animal feed.

EXAMPLE 3 Effect of Administering Red Clover Extract to Humans

Seven normal individuals were studied for the comparative effects of red clover extract and whole legumes on blood cholesterol levels. All the individuals were consuming a standard Western diet with minimal levels of legumes.

Three men consumed between 100-150 g haricot or navy beans daily for 3 weeks as a supplement to their normal diet. This yielded an approximate daily isoflavone dosage or between 60-100 mg.

Four other individuals (3 men, 1 women) consumed 5 g of red clover extract containing 100 mg isoflavones daily for 3 weeks.

Total serum cholesterol levels were determined immediately before and immediately following the challenge.

Pre-treatment Post-treatment % change
Beans only
Patient 1 5.77 5.46 −5.4
Patient 2 6.24 6.12 −1.9
Patient 3 7.45 8.51 +14.3
Red clover extract
Patient 5 6.53 5.90 −9.6
Patient 6 7.43 6.63 −10.08
Patient 7 6.33 5.50 −13.1
Patient 8 6.98 7.28 +4.3

The red clover extract had a significantly (P<0.05) greater hypocholesterolaemic effect than did the whole beans.

Neither of the treatments produced any untoward side effects, although the whole bean eaters reported greater difficulty with compliance of treatment than did those taking the red clover extract.

EXAMPLE 4 Effect of Administering Soy Hypocotyls to Humans

Fifteen volunteers (8 women, 7 men) were given 5 g of soy hypocotyl containing (45 mg daidzein and 5 mg genistein) daily for 2 months. The hypocotyl was consumed as a powder added to the diet.

The effects on cholesterol levels are shown in the following table. The individuals are grouped according to their pre-treatment cholesterol levels (high, medium, low).

Range (mean) unmol/L
n Pre-treatment Post-treatment
Group 1 6 6.3-8.4 (7.1) 5.4-6.5 (6.1)
Group 2 6 5.0-6.2 (5.5) 4.7-5.9 (5.1)
Group 3 3 3.3-4.7 (4.2) 3.4-4.6 (4.1)

The results show a significant fall in total cholesterol levels in those individuals with cholesterol levels considered to be at the upper end of the normal range.

In addition, 1 women reported substantial amelioration of her benign breast disease problem associated with mid-cycle swelling and tenderness, and another women reported regularisation of her menstrual cycle and reduced menstrual bleeding. Both of these effects were regarded as beneficial.

No other side-effects were reported as a result of the treatment.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3471520Dec 30, 1965Oct 7, 1969Merck Ag E4-aryl-isoflavanoids
US3535344Feb 13, 1967Oct 20, 1970Merck Ag E3,4-cis-4-aryl-isoflavanes
US3973608May 19, 1975Aug 10, 1976Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiMicrobial production of certain isoflavones
US4157984Jun 8, 1977Jun 12, 1979Z-L LimitedAntioxidants, antioxidant compositions and methods of preparing and using same
US4200692Sep 26, 1977Apr 29, 1980Projektierung Chemische Verfahrenstechnik GmbhProcess for the production of xylose by enzymatic hydrolysis of xylan
US4232122Jan 17, 1979Nov 4, 1980Z-L Limited PartnershipAntioxidants, antioxidant compositions and methods of preparing and using same
US4264509Apr 11, 1979Apr 28, 1981Z-L Limited PartnershipIsoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4301251Feb 6, 1980Nov 17, 1981Rumyantseva Galina NProcess for producing rose oil
US4366082Jan 12, 1981Dec 28, 1982Z-L Limited PartnershipIsoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4379177 *Dec 9, 1981Apr 5, 1983The Procter & Gamble CompanyStable dehydrated cocrystalline amino acid food additives
US4390559Jan 12, 1981Jun 28, 1983Z-L Limited PartnershipIsoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4428876Jun 17, 1983Jan 31, 1984Tokiwa Kanpo Pharmaceutical Co., Ltd.Process for isolating saponins and flavonoids from leguminous plants
US4557927Feb 22, 1984Dec 10, 1985Kabushiki Kaisha HoyashibaraFood products and process for producing same
US4814346Nov 4, 1987Mar 21, 1989Zyma SaBenzopyrans and use thereof in treating vascular diseases
US5141746Oct 16, 1990Aug 25, 1992Nestec S.A.Process for obtaining genistin malonate and daidzin malonate
US5153230Feb 1, 1991Oct 6, 1992Perfective Cosmetics, Inc.Topical skin cream composition
US5247102Apr 6, 1990Sep 21, 1993Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt.Process for the preparation of substituted isoflavone derivative
US5320949Oct 12, 1993Jun 14, 1994Protein Technologies International, Inc.Process for producing aglucone isoflavone enriched vegetable protein fiber
US5352384Jan 13, 1994Oct 4, 1994Protein Technologies International, Inc.Aglucone isoflavone enriched vegetable protein fiber
US5424331Jun 10, 1994Jun 13, 1995Bio-Virus Research IncorporatedPharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
US5498631Aug 1, 1994Mar 12, 1996Tufts University School Of MedicineMethod for treatment of menopausal and premenstrual symptoms
US5506211May 9, 1994Apr 9, 1996The Uab Research FoundationGenistein for use in inhibiting osteroclasts
US5516528Jan 13, 1995May 14, 1996Wake Forest UniversityDietary phytoestrogen in estrogen replacement therapy
US5523087Feb 15, 1995Jun 4, 1996Bio-Virus Research IncorporatedPharmaceutical compositions for the treatment of diabetic male sexual dysfunction
US5530112Nov 16, 1992Jun 25, 1996Gb R&D, C LimitedGel production from plant matter
US5547866Jul 20, 1994Aug 20, 1996The Regents Of The University Of CaliforniaTaxane production in haploid-derived cell cultures
US5554519Aug 7, 1995Sep 10, 1996Fermalogic, Inc.Process of preparing genistein
US5569459Feb 15, 1995Oct 29, 1996Bio-Virus Research IncorporatedPharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5637561Sep 21, 1994Jun 10, 1997Protein Technologies International, Inc.Aglucone isoflavone enriched vegetable protein whey, whey protein, and process for producing
US5639785Jun 7, 1995Jun 17, 1997Global Pharma, Ltd.Methods for the treatment of baldness and gray hair using isoflavonoid derivatives
US5679806Feb 24, 1995Oct 21, 1997Hauser, Inc.Process for the isolation and purification of isoflavones
US5700669Apr 12, 1995Dec 23, 1997Bristol-Myers Squibb CompanyEnzymatic hydrolysis method for the conversion of C-7 sugar to C-7 hydroxyl taxanes
US5702752Mar 13, 1996Dec 30, 1997Archer Daniels Midland CompanyProduction of isoflavone enriched fractions from soy protein extracts
US5726034Sep 6, 1996Mar 10, 1998Protein Technologies International, Inc.Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US5733926Dec 13, 1996Mar 31, 1998Gorbach; Sherwood L.Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5763389Sep 21, 1994Jun 9, 1998Protein Technologies International, Inc.Aglucone isoflavone enriched vegetable protein extract and isolate and process for producing
US5789581Apr 10, 1996Aug 4, 1998Kikkoman CorporationProcess for obtaining malonyl isoflavone glycosides and obtaining isoflavone glycosides or isoflavone aglycons from malonyl isoflavone glycosides
US5792503Jun 4, 1997Aug 11, 1998Archer Daniels Midland CompanyProduction of isoflavone enriched fractions from soy protein extracts
US5804234Sep 13, 1996Sep 8, 1998Suh; John D.Plant protein for nutritional products and method of making same
US5830887May 19, 1993Nov 3, 1998Novogen Research Pty. Ltd.Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US5855892Sep 19, 1997Jan 5, 1999Potter; Susan M.Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5942539Oct 3, 1997Aug 24, 1999Wake Forest UniversityMethods of treating or preventing endometriosis with phytoestrogens
US6004558Feb 25, 1998Dec 21, 1999Novogen, Inc.Methods for treating cancer with legume plant extracts
US6060070Jun 11, 1997May 9, 2000Gorbach; Sherwood L.Isoflavonoids for treatment and prevention of aging skin and wrinkles
US6146668Apr 28, 1997Nov 14, 2000Novogen, Inc.Preparation of isoflavones from legumes
US6235773Jan 28, 2000May 22, 2001The Procter & Gamble CompanyCompositions for regulating skin appearance
US6340703May 1, 1998Jan 22, 2002Novogen, Inc.Treatment or prevention of osteoporosis
US6455032Dec 21, 1998Sep 24, 2002Novogen Research Pty. Ltd.Composition and method for protecting skin from UV induced immunosuppression and skin damage
US6497906Apr 11, 2000Dec 24, 2002Novogen Research Pty. Ltd.Dietary supplements comprising soy hypocotyls containing at least one isoflavone
US6562380Aug 13, 1997May 13, 2003Novogen Research Pty LimitedMethods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen
US6599536Mar 26, 1999Jul 29, 2003Novogen Research Pty LtdTherapy of estrogen-associated disorders
US6642212Oct 19, 1999Nov 4, 2003Novogen Research Pty. Ltd.Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6649648Aug 29, 1997Nov 18, 2003Novogen Research Pty LimitedTherapeutic methods and compositions involving isoflavones
US6987098Jul 2, 2003Jan 17, 2006Novogen Research Pty. Ltd.Health supplement
US7045155Oct 21, 2002May 16, 2006Novogen Research Pty Ltd.Dietary supplements comprising soy hypocotyls containing at least one isoflavone
US20020035074Nov 9, 2001Mar 21, 2002Novogen, Inc.Treatment or prevention of menopausal symptoms and osteoporosis
US20020198248Jun 21, 2002Dec 26, 2002Novogen Research Pty LimitedTherapeutic methods and compositions involving isoflavones
US20030018060Jun 21, 2002Jan 23, 2003Novogen Research Pty LimitedTherapeutic methods and compositions involving isoflavones
US20030059384Aug 5, 2002Mar 27, 2003Novogen Research Pty. Ltd.Compositions and method for protecting skin from UV induced immunosuppression and skin damage
US20030078214Oct 21, 2002Apr 24, 2003Novogen Research Pty. Ltd.Dietary supplements comprising soy hypocotyls containing at least one isoflavone
US20030157225Jan 22, 2001Aug 21, 2003Husband Alan JamesFood product and process
US20030219499Jun 12, 2003Nov 27, 2003Novogen Research Pty LtdTherapy of estrogen-associated disorders
US20040048812Jul 2, 2003Mar 11, 2004Novogen Research Pty. Ltd.Health supplement
US20040072765Jun 18, 2003Apr 15, 2004Novogen Research Pty Ltd.Cardiovascular and bone treatment using isoflavones
US20040116498Jan 16, 2002Jun 17, 2004Husband Alan JamesRegulations of lipids and/or bone density and compositions therefor
AU1022795A Title not available
AU2481397A Title not available
AU2771400A Title not available
AU7307298A Title not available
AU8065587A Title not available
DE4432947A1Sep 16, 1994Mar 21, 1996New Standard GmbhSkin-treating agent contg. isoflavone or deriv.
EP0129667A1Apr 25, 1984Jan 2, 1985Takeda Chemical Industries, Ltd.Compounds and pharmaceutical compositions for treatment of hypoovarianism
EP0135172A2Aug 22, 1984Mar 27, 1985Takeda Chemical Industries, Ltd.Method for treatment of osteoporosis
EP0136569A2Sep 1, 1984Apr 10, 1985Takeda Chemical Industries, Ltd.Isoflavone derivatives, their production and use
EP0412211A1Aug 2, 1989Feb 13, 1991Therapeutical Systems CorporationCancer therapy system
EP0426998A2Oct 10, 1990May 15, 1991Societe Des Produits Nestle S.A.Process for the preparation of isoflavanones
EP0671170A1Feb 21, 1995Sep 13, 1995Bristol-Myers Squibb CompanyUse of pravastatin for slowing progression coronary artery atherosclerosis
EP0682877A1Dec 14, 1994Nov 22, 1995Nichimo Company LimitedProcess for producing product from pulse and food containing product from pulse
EP0795553A1Mar 11, 1997Sep 17, 1997Archer Daniels Midland CompanyProduction of isoflavone enriched fractions from soy protein extracts
EP0906761A2Oct 2, 1998Apr 7, 1999Archer Daniels Midland CompanyMethod of preparing and using phytochemicals
GB1322844A Title not available
GB1482238A Title not available
GB1495189A Title not available
JPH0267218A Title not available
JPH01226824A Title not available
JPH01258669A Title not available
JPS503539A Title not available
JPS6442427A Title not available
JPS50101360A Title not available
JPS50160483A Title not available
JPS61246124A Title not available
JPS61247396A Title not available
JPS62106016A Title not available
JPS62106017A Title not available
JPS62126186A Title not available
Non-Patent Citations
Reference
1Adlercreutz, H. et al., "Effect of Dietary Components, Including Lignans and Phytoestrogens, on Enterohepatic Circulation and Liver Metabolism of Estrogens and on Sex Hormones Binding Globulin (SHBG)," J. steroid Biochem, vol. 27, No. 4-6, pp. 1135-1144 (1987).
2Akkad, Andrea A. et al., "Abnormal Uterine Bleeding on Hormone Replacement: The Importance of Intrauterine Structural Abnormalities," Obstetrics & Gynecology, vol. 86, pp. 330-334 (1995).
3Alegrio, L.V. et al.; "Diarylheptanoids and Isoflavonoids from Centrolobium Species"; Phytochemistry, vol. 28, No. 9, pp. 2359-2362, (1989).
4Al-Maharik, N.I. et al., "Synthesis of C-C-Bridged Bis-Isoflavones," J. Org. Chem., vol. 65, pp. 2305-2308, (2000).
5Amendment After Final filed in U.S .Patent No. 6,146,668 on Dec. 7, 1999.
6Amendment After Final filed in U.S. Appl. No. 09/647,092 on Dec. 17, 2002.
7Amendment and Response filed in U.S. Pat No. 6,146,668 on Mar. 8, 1999.
8Amendment and Response to Restriction Requirement filed in U.S. Appl. No. 09/647,092 on Mar. 11, 2003.
9Amendment and Responses filed in U.S. Appl. No. 09/986,509 on Aug. 5, 2004.
10Amendment and Responses filed in U.S. Pat. No. 6,340,703 on Oct. 27, 2000.
11Amendment filed in U.S. Appl. No. 09/546,565 on Apr. 2, 2003.
12Amendment filed in U.S. Appl. No. 09/546,565 on Aug. 25, 2004.
13Amendment filed in U.S. Appl. No. 09/546,565 on Jan. 26, 2005.
14Amendment filed in U.S. Appl. No. 09/546,565 on Nov. 20, 2003.
15Amendment filed in U.S. Appl. No. 09/647,092 on Mar. 25, 2002.
16Amendment filed in U.S. Appl. No. 09/986,509 on Dec. 23, 2002.
17Amendment filed in U.S. Appl. No. 10/600,004 on Dec. 13, 2004.
18Amendment filed in U.S. Pat. No. 6,340,703 on May 31, 2001.
19Anderson et al. "Biphasic Effects of Genistein on Bone Tissue in the Ovariectomized, Lactating Rat Model," P.S. E. B. M. vol. 217, pp. 345-350 (1998).
20Bezuidenhoudt et al., "Synthesis of Isoflavanoid Oligomers Using a Pterocarpan as Inceptive Electrophile," J. Chem. Soc. Perkin Transactions I, pp. 2767-2778 (1984).
21Bingham et al., "Phyto-oestrogens: where are we now?," British Journal of Nutrition, vol. 79, pp. 393-406 (1998).
22Constantinou, A. et al., "Induction of Differentiation and DNA Strand Breakage in Human HL-60 and K-562 Leukemia Cells by Genistein," Cancer Res.50:2618-2624 (1990).
23Kiguchi, K. et al., "Genistein-Induced Cell Differentittion and Protein-Linked DNA Strand Breakage in Human Melanoma Cells," Cancer Comm.2(8):271-278 (1990).
24Liu, Y. et al., "Effects of solid dispersion of daidzein on the blood pressure of spontaneously hypertensive rates," Chemical Abstracts, 115(8):406, Abstract No. 78763p (1991).
25Naim, M. et al., "Antioxidative and Antihemolytic Activities of Soybean Isoflavones," J. Agric. Food Chem. 24(6):1174-1177 (1976).
26Notice of Allowance with Examiner's Amendment issued in U.S. Appl. No. 09/546,565 on Nov. 16, 2004.
27Notice of Allowance with Examiner's Amendment issued in U.S. Patent No. 6,146,668 on Jan. 11, 2000.
28Notice of Allowance with Statement of Reasons issued in U.S. Appl. No. 09/647,092 on Apr. 8, 2003.
29Oenobiol Feminite Dietary Supplement, International Product Alert 16(12) (1999), and Oenobiol Product Insert ( 3 pages).
30Office Action in U.S. Pat. No. 6,340,703 on Feb. 9, 2001.
31Office Action issued in U.S Appl. No. 09/546,565 on Jun. 20, 2003.
32Office Action issued in U.S. Appl. No. 09/546,565 on Feb. 25, 2004.
33Office Action issued in U.S. Appl. No. 09/546,565 on Oct. 2, 2002.
34Office Action issued in U.S. Appl. No. 09/647,092 on Jun. 18, 2002.
35Office Action issued in U.S. Appl. No. 09/914,035 on Dec. 18, 2002.
36Office Action issued in U.S. Appl. No. 09/986,509 on Feb. 6, 2004.
37Office Action issued in U.S. Appl. No. 09/986,509 on Jul. 23, 2002.
38Office Action issued in U.S. Appl. No. 10/600,004 on Jun. 17, 2004.
39Office Action issued in U.S. Pat. No. 6,340,703 on Apr. 27, 2000.
40Office Action issued in U.S. Pat. No. 6,340,703 on Jul. 9, 1999.
41Office Action issued in U.S. Patent No. 6,146,668 on Jun. 7, 1999.
42Office Action issued in U.S. Patent No. 6,146,668 on Sep. 9, 1998.
43Office Action issued inU.S. Appl. No. 09/647,092 on Oct. 23, 2001.
44Office Action mailed in U.S. Appl. No. 10/611,087 on Mar. 27, 2006.
45Office Action mailed in U.S. Appl. No. 10/611,087 on Nov. 14, 2006.
46Okura, A. et al., "Effect of Genistein on Topoisomerase Activity and on the Growth of [Val 12]Ha-ras-transformed NIH 3T3 Cells," Biochem. Biophys. Res. Comm. 157(1):183-189 (1988).
47Partial European Search Report for EP 04103669, dated Dec. 22, 2004.
48Peterson et al. "Genistein Inhibition of the Growth of Human Breast Cancer Cells: Independence from Estrogen Receptors and the Multi-Drug Resistance Gene," Biochemical ad Biophysical Research Communications, vol. 179, No. 1, pp. 661-667 (Aug. 30, 1991).
49Preliminary Amendment filed in U.S. Appl. No. 09/546,565 on Apr. 11, 2000.
50Preliminary Amendment filed in U.S. Appl. No. 10/459,537 on Jun. 12, 2003.
51Preliminary Amendment filed in U.S. Appl. No. 10/600,004 on Jun. 18, 2003.
52Preliminary Amendment filed in U.S. Appl. No. 11/490,865 on Jul. 20, 2006.
53Response filed in U.S. Appl. No. 10/611,087 on Jun. 26, 2006.
54Response filed in U.S. Appl. No. 10/611,087 on Oct. 12, 2005.
55Response in Restriction Requirement filed in U.S. Appl. No. 09/986,509 on Oct. 8, 2003.
56Restriction Requirement issued in U.S. Appl. No. 09/647,092 on Feb. 10, 2003.
57Restriction Requiremnet issued in U.S. Appl. No. 09/986,509 on Apr. 18, 2003.
58 *Sharma, Atherosclerosis, (1979), vol. 33, pp. 371-375.
59Statuory Declaration of G. Clements, declared Jan. 27, 1999, 2 pages.
60Statuory Declaration of Julie Hill, declared Apr. 4, 1998, 2 pages.
61Statuory Declaration of Ngaire Petit-Young, declared Nov. 5, 1998, 3 pages.
62Statutory Declaration of Fiona Bathgate (Amended), declared Oct. 26, 1998, 2 pages.
63Statutory Declaration of Fiona Bathgate, declared Mar. 24, 1998, 4 pages.
64Statutory Declaration of Graham Edmund Kelly with two Exhibits (GK1 and GK2), dated Oct. 22, 2003.
65Statutory Declaration of Hubert Regtop, declared Nov. 24, 1998, 53 pages.
66Statutory Declaration of Jennifer Carpinelli, declared Oct. 21, 1998, 2 pages.
67Statutory Declaration of Joseph Nicolas Van Haaster, declared Jan. 26, 1999, including Exhibit "JNVH-1", 20 pages.
68Statutory Declaration of Kerry Martin Bone, declared Oct. 5, 1998, 31 pages.
69Statutory Declaration of Nancy Beckham, declared Sep. 8, 1998, 20 pages.
70Statutory Declaration of Norbert Krause, declared Nov. 5, 1998, 23 pages.
71Supplementary European Search Report for EP 93 90 9679, dated Apr. 25, 1997, 3 pages.
72Tamura, S. et al., "Chemical Studies on 'Clover Sickness.' Part I. Isolution and Structural Elucidation of Two New Isoflavonoids in Red Clover," Agr. Biol. Chem. 33(3):391-397 (1969).
73U.S. Appl. 10/600,004 filed Jun. 18, 2003, Kelly et al.
74U.S. Appl. No. 09/421,069 filed Oct. 19, 1999, Kelley.
75U.S. Appl. No. 09/546,565 filed Apr. 11, 2000, Kelly et al.
76U.S. Appl. No. 09/986,509 filed Nov. 9, 2001, Kelly.
77U.S. Appl. No. 10/176,762 filled Jun. 21,2002, Kelly et al.
78U.S. Appl. No. 10/177,387 filed Jun. 21, 2002, Kelly et al.
79U.S. Appl. No. 10/181,549 filed Jan. 22, 2001, Husband et al.
80U.S. Appl. No. 10/212,847 filed Aug. 5, 2002, Kelly et al.
81U.S. Appl. No. 10/250,858 filed Jan. 16, 2002, Husband.
82U.S. Appl. No. 10/274,371 filed Oct. 21, 2002, Kelly.
83U.S. Appl. No. 10/421,659 filed Apr. 22, 2003, Kelly.
84U.S. Appl. No. 10/459,537 filed Jun. 12, 2003, Kelly et al.
85U.S. Appl. No. 10/469,957 filed Mar. 8, 2002, Heaton et al.
86U.S. Appl. No. 10/471,668 filed Mar. 15, 2002, Husband et al.
87U.S. Appl. No. 10/493,390 filed Oct. 25, 2002, Kelly et al.
88U.S. Appl. No. 10/510,837 filed Oct. 8, 2004, Kelly et al.
89U.S. Appl. No. 10/611,087 filed Jul. 2, 2003, Kelly.
90U.S. Appl. No. 10/611,151 filed Jul. 2, 2003, Kelly.
91U.S. Appl. No. 10/636,902 filed Aug. 6, 2003, Kelly et al.
92U.S. Appl. No. 10/704,385 filed Nov. 7, 2003, Heaton et al.
93U.S. Appl. No. 10/799,022 filed Mar. 11, 2004, Kelly.
94U.S. Appl. No. 10/851,270 filed Mar. 20, 2004, Heaton et al.
95U.S. Appl. No. 10/947,356 filed Sep. 21, 2004, Kelly et al.
96U.S. Appl. No. 11/024,512 filed Dec. 28, 2004, Kelly et al.
97Van De Weijer, P. et al., "Isoflavones from red clover (Promensil(R)) significantly reduce menopausal hot flush symptoms compared with placebo," Maturitas 42:187-193 (2002).
98Wei et al. "Antioxidant and Antipromitional Effects of the Soybean Isoflavone Genistein," Proceedings of the Society for Experimental Biology and Medicine, vol. 208, No. 1, pp. 124-130 (Oct. 1993).
99Yamashita, Y. et al., "Induction of mammalial topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, Genistein and Orobol," Biochem. Pharmacol. 39(4):737-744 (1990).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US20110305782 *Dec 15, 2011Novogen Research Pty Ltd.Methods of cholesterol reduction using isoflavones
US20120003337 *Jan 5, 2012Novogen Research Pty Ltd.Health supplements containing phyto-oestrogens, analogues or metabolites thereof
Classifications
U.S. Classification514/182, 424/449, 424/451, 426/545, 424/423, 514/25, 549/406, 424/464, 549/403
International ClassificationA61K31/7048, A61P13/08, A61K31/565, A61K36/185, A61P1/00, A61K31/352, A23L1/30, A61K31/704, A61P13/02, A61P35/00, A61P5/00, A61P3/06, A23L1/20, A61P15/12, A61K45/06, A61K9/20, A61K9/48, A61K36/48, A61K36/00, A61K31/35, A61K38/22, A61K31/353, A61P15/00, A61K38/08, A61K31/56, A01N43/04, A61K31/70
Cooperative ClassificationA23L1/3004, A61K31/353, A61K36/185, A23L1/2006, A61K31/35, A23L1/2005, A61K31/7048, A61K38/08, A61K36/48
European ClassificationA61K31/35, A23L1/20D4, A61K31/353, A23L1/30B2, A23L1/20D, A61K36/185, A61K36/48, A61K31/7048, A61K38/08
Legal Events
DateCodeEventDescription
Apr 21, 2010FPAYFee payment
Year of fee payment: 12